Skip to content

Quality of Life in Breast Cancer Survivors Who Were Pregnant During Their Cancer Treatment

Quality of Life in Breast Cancer Survivors Who Were Pregnant During Their Cancer Treatment

Status
Terminated
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07191496
Enrollment
30
Registered
2025-09-24
Start date
2025-10-01
Completion date
2026-04-09
Last updated
2026-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer Survivor, Pregnant Women, Quality of Lifte

Brief summary

To assess the quality of life for women who were pregnant during their breast cancer treatment.

Detailed description

Primary Objectives Provide preliminary data to describe the current QOL of breast cancer survivors who received cancer treatment while pregnant. Secondary Objectives Identify the relationship between QOL and anxiety, depression, fear of cancer recurrence, and social support in breast cancer survivors, who received treatment while pregnant.

Interventions

OTHERQuestionnaire

The questionnaires include the Ferrans and Powers QLI, EORTC QLQ-C30, FCR-7 Scale, HADS, and MOS Social Support Survey.

Sponsors

M.D. Anderson Cancer Center
Lead SponsorOTHER

Study design

Observational model
CASE_CROSSOVER
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
FEMALE
Healthy volunteers
No

Inclusion criteria

Eligibility Criteria * Female, any current age and any age at diagnosis * Documented diagnosis of breast cancer during pregnancy * Documentation of receiving chemotherapy during pregnancy * Alive with no evidence of disease at time of recruitment * Able to reach and speak English

Exclusion criteria

* Any woman who delayed and received their chemotherapy after delivery. * Any woman who was diagnosed with breast cancer before or after their pregnancy. * Any woman whom there is documentation of inability to provide consent in the medical record

Design outcomes

Primary

MeasureTime frame
QOL QuestionnairesThrough study completion; an average of 1 year

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOREileen Hacker, MD

M.D. Anderson Cancer Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 18, 2026